

सर्वप्रथम पत्रिका

INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

SARITA DEVI

CHHITAR MAL PALSANIA

01/07/1991

Bank Account Number

CEPDPD0155G

DR. U. C. GUPTA  
MBBS, MD (Physician)  
RMC No. 281

Signature

Handwritten signature

Scanned by TapScanner



# P3 HEALTH SOLUTIONS LLP

(ASSOCIATES OF MAXCARE DIAGNOSTICS)

- B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023
- +91 141 4824885 maxcarediagnostics1@gmail.com



## General Physical Examination

Date of Examination: 11/02/23

Name: SARITA DEVI Age: 31/YRS DOB: 01/07/1991 Sex: Female

Referred By: BANK OF BARODA

Photo ID: PAN CARD ID #: CEJPD001554

Ht: 162 (cm)

Wt: 64 (Kg)

Chest (Expiration): 91 (cm)

Abdomen Circumference: 86 (cm)

Blood Pressure: 120/80 mm Hg

PR: 75 / min

RR: 18 / min

Temp: Afebrile

BMI 24

Eye Examination: R/EY GIC, NIC, NCB  
L/EY GIC, NIC, NCB

Other: No

On examination he/she appears physically and mentally fit:  Yes /  No

Signature Of Examinee : सरिता देवी

Name of Examinee: SARITA DEVI

Signature of Dr. Dr. U. C. GUPTA  
MBBS, MD (Physician)  
RMC No. 291

Name of Examinee Dr U.C. Gupta





B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME :- **Mrs. SARITA DEVI**

Patient ID :-12223042 Date :- 11/02/2023 09:02:28

Age :- 31 Yrs 7 Mon 13 Days

Ref. By Doctor:-BANK OF BARODA

Sex :- Female

Lab/Hosp :-

Company :- Mr.MEDIWHEEL

Final Authentication : 11/02/2023 18:29:58

**HAEMATOLOGY**

Test Name	Value	Unit	Biological Ref Interval
-----------	-------	------	-------------------------

FULL BODY HEALTH CHECKUP BELOW 40 FEMAL

**HAEMOGARAM**

**HAEMOGLOBIN (Hb)** 12.7 g/dL 12.0 - 15.0

**TOTAL LEUCOCYTE COUNT** 4.00 /cumm 4.00 - 10.00

**DIFFERENTIAL LEUCOCYTE COUNT**

NEUTROPHIL 53.0 % 40.0 - 80.0

LYMPHOCYTE 40.0 % 20.0 - 40.0

EOSINOPHIL 3.0 % 1.0 - 6.0

MONOCYTE 4.0 % 2.0 - 10.0

BASOPHIL 0.0 % 0.0 - 2.0

TOTAL RED BLOOD CELL COUNT (RBC) 4.07 x10<sup>6</sup>/uL 3.80 - 4.80

HEMATOCRIT (HCT) 39.20 % 36.00 - 46.00

MEAN CORP VOLUME (MCV) 97.0 fL 83.0 - 101.0

MEAN CORP HB (MCH) 31.3 pg 27.0 - 32.0

MEAN CORP HB CONC (MCHC) 32.4 g/dL 31.5 - 34.5

**PLATELET COUNT** 235 x10<sup>3</sup>/uL 150 - 410

RDW-CV 13.9 % 11.6 - 14.0

MENTZER INDEX **23.83 H** 0.00 - 13.00

A complete blood picture (CBP) is a kind of blood test that is done to assess a person's overall health and diagnose a wide range of health disorders like leukemia, anemia and other infections.

A complete blood count (CBC) is a complete blood test that diagnose many components and features of a persons blood which includes: -

- \*Red Blood Cells (RBC), which carry oxygen -
- \*White Blood Cells (WBC), which help in fighting against infections -
- \*Hemoglobin, which is the oxygen carrying protein in the red blood cells -
- \*Hematocrit (HCT), the proportion of RBC to the fluid component, or plasma present in blood -
- \*Platelets, which aid in blood clotting

(CBC): Methodology: TLC,TRBC,PCV,PLT Impedance method, HB Calorimetric method, and MCH,MCV,MCHC,MENTZER INDEX are calculated. InstrumentName: MINDRAY BC-3000 Plus 3 part automatic analyzer,

VIKARANTJI

**Technologist**

Page No: 1 of 16


**DR.TANU RUNGTA**

MD (Pathology)

RMC No. 17226



B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME :- <b>Mrs. SARITA DEVI</b>	Patient ID :-12223042	Date :- 11/02/2023	09:02:28
Age :- 31 Yrs 7 Mon 13 Days	Ref. By Doctor:-BANK OF BARODA		
Sex :- Female	Lab/Hosp :-		
	Company :- Mr.MEDIWHEEL		

Final Authentication : 11/02/2023 18:29:58

### HAEMATOLOGY

**Erythrocyte Sedimentation Rate (ESR)**

14

mm in 1st hr

00 - 20

Method:- Westergreen

The erythrocyte sedimentation rate (ESR or sed rate) is a relatively simple, inexpensive, non-specific test that has been used for many years to help detect inflammation associated with conditions such as infections, cancers, and autoimmune diseases. ESR is said to be a non-specific test because an elevated result often indicates the presence of inflammation but does not tell the health practitioner exactly where the inflammation is in the body or what is causing it. An ESR can be affected by other conditions besides inflammation. For this reason, the ESR is typically used in conjunction with other tests, such as C-reactive protein. ESR is used to help diagnose certain specific inflammatory diseases, including temporal arteritis, systemic vasculitis and polymyalgia rheumatica. (For more on these, read the article on Vasculitis.) A significantly elevated ESR is one of the main test results used to support the diagnosis. This test may also be used to monitor disease activity and response to therapy in both of the above diseases as well as



VIKARANTJI

**Technologist**

Page No: 2 of 16

**DR. TANU RUNGTA**


MD (Pathology)

RMC No. 17226





B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME :- Mrs. SARITA DEVI	Patient ID :-12223042	Date :- 11/02/2023	09:02:28
Age :- 31 Yrs 7 Mon 13 Days	Ref. By Doctor:-BANK OF BARODA		
Sex :- Female	Lab/Hosp :-		
	Company :- Mr.MEDIWHEEL		

Final Authentication : 11/02/2023 18:29:58


**BIOCHEMISTRY**

Test Name	Value	Unit	Biological Ref Interval
FASTING BLOOD SUGAR (Plasma) Method:- GOD POD	101.0	mg/dl	70.0 - 115.0
Impaired glucose tolerance (IGT)		111 - 125 mg/dL	
Diabetes Mellitus (DM)		> 126 mg/dL	

Instrument Name: HORIBA CA60 Interpretation: Elevated glucose levels (hyperglycemia) may occur with diabetes, pancreatic neoplasm, hyperthyroidism and adrenal cortical hyper-function as well as other disorders. Decreased glucose levels (hypoglycemia) may result from excessive insulin therapy or various liver diseases .

BLOOD SUGAR PP (Plasma) 103.0 mg/dl 70.0 - 140.0  
Method:- GOD PAP

Instrument Name: HORIBA Interpretation: Elevated glucose levels (hyperglycemia) may occur with diabetes, pancreatic neoplasm, hyperthyroidism and adrenal cortical hyper-function as well as other disorders. Decreased glucose levels (hypoglycemia) may result from excessive insulin therapy or various liver diseases .




VIKARANTJI

**Technologist**  
Page No: 4 of 16

**DR. TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226



B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME: Mrs. SARITA DEVI	Patient ID :-12223042	Date :- 11/02/2023	09:02:28
Age :- 31 Yrs 7 Mon 13 Days	Ref. By Doctor:-BANK OF BARODA		
Sex :- Female	Lab/Hosp :-		
	Company :- Mr.MEDIWHEEL		

Final Authentication : 11/02/2023 18:29:58

**HAEMATOLOGY**

Test Name	Value	Unit	Biological Ref Interval
<b>GLYCOSYLATED HEMOGLOBIN (HbA1C)</b> Method:- CAPILLARY with EDTA	5.6	mg%	Non-Diabetic < 6.0 Good Control 6.0-7.0 Weak Control 7.0-8.0 Poor control > 8.0
MEAN PLASMA GLUCOSE Method:- Calculated Parameter	114	mg/dL	68 - 125

**INTERPRETATION**

AS PER AMERICAN DIABETES ASSOCIATION (ADA)  
Reference Group HbA1c in %  
Non diabetic adults >=18 years < 5.7  
At risk (Prediabetes) 5.7 - 6.4  
Diagnosing Diabetes >= 6.5

**CLINICAL NOTES**

In vitro quantitative determination of HbA1c in whole blood is utilized in long term monitoring of glycemia. The HbA1c level correlates with the mean glucose concentration prevailing in the course of the patient's recent history (approx - 6-8 weeks) and therefore provides much more reliable information for glycemia monitoring than do determinations of blood glucose or urinary glucose. It is recommended that the determination of HbA1c be performed at intervals of 4-6 weeks during Diabetes Mellitus therapy. Results of HbA1c should be assessed in conjunction with the patient's medical history, clinical examinations and other findings.  
Some of the factors that influence HbA1c and its measurement [Adapted from Gallagher et al ]

**1. Erythropoiesis**

- Increased HbA1c: iron, vitamin B12 deficiency, decreased erythropoiesis.  
- Decreased HbA1c: administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic liver disease.

**2. Altered Haemoglobin-Genetic or chemical alterations in hemoglobin: hemoglobinopathies, HbF, methemoglobin, may increase or decrease HbA1c.**

**3. Glycation**

- Increased HbA1c: alcoholism, chronic renal failure, decreased intraerythrocytic pH.  
- Decreased HbA1c: certain hemoglobinopathies, increased intra-erythrocyte pH

**4. Erythrocyte destruction**

- Increased HbA1c: increased erythrocyte life span: Splenectomy.  
- Decreased A1c: decreased RBC life span: hemoglobinopathies, splenomegaly, rheumatoid arthritis or drugs such as antiretrovirals, ribavirin & dapsona.

**5. Others**

- Increased HbA1c: hyperbilirubinemia, carbamylated hemoglobin, alcoholism, large doses of aspirin, chronic opiate use, chronic renal failure  
- Decreased HbA1c: hypertriglyceridemia, reticulocytosis, chronic liver disease, aspirin, vitamin C and E, splenomegaly, rheumatoid arthritis or drugs

**Note:**

1. Shortened RBC life span -HbA1c test will not be accurate when a person has a condition that affects the average lifespan of red blood cells (RBCs), such as hemolytic anemia or blood loss. When the lifespan of RBCs in circulation is shortened, the A1c result is falsely low and is an unreliable measurement of a person's average glucose over time.  
2. Abnormal forms of hemoglobin - The presence of some hemoglobin variants, such as hemoglobin S in sickle cell anemia, may affect certain methods for measuring A1c. In these cases, fructosamine can be used to monitor glucose control.

**Advised:**

1. To follow patient for glycemic control test like fructosamine or glycated albumin may be performed instead.  
2. Hemoglobin HPLC screen to analyze abnormal hemoglobin variant.  
estimated Average Glucose (eAG) : based on value calculated according to National Glycohemoglobin Standardization Program (NGSP) criteria.

VIKARANTJI

**Technologist**

Page No: 5 of 16

*Tanu*

**DR. TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226





# P3 HEALTH SOLUTIONS LLP

(ASSOCIATES OF MAXCARE DIAGNOSTICS)



B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME: ~~4188~~ **Mrs. SAKITA DEVI** diagnostics1@gmail.com

Patient ID :-12223042 Date :- 11/02/2023 09:02:28

Age :- 31 Yrs 7 Mon 13 Days

Ref. By Doctor:-BANK OF BARODA

Sex :- Female

Lab/Hosp :-

Company :- Mr.MEDIWHEEL

Final Authentication : 11/02/2023 18:29:58

## HAEMATOLOGY

BLOOD GROUP ABO

Method:- Haemagglutination reaction

"O" POSITIVE



VIKARANTJI

**Technologist**

Page No: 6 of 16

**DR.TANU RUNGTA**

MD (Pathology)

RMC No. 17226



B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME : Mrs. SAGITA DEVI  
Age :- 31 Yrs 7 Mon 13 Days  
Sex :- Female  
Patient ID :-12223042 Date :- 11/02/2023 09:02:28  
Ref. By Doctor:-BANK OF BARODA  
Lab/Hosp :-  
Company :- Mr.MEDIWHEEL

Final Authentication : 11/02/2023 18:29:58

**BIOCHEMISTRY**

Test Name	Value	Unit	Biological Ref Interval
-----------	-------	------	-------------------------

**LIPID PROFILE**

TOTAL CHOLESTEROL 197.00 mg/dl  
Desirable <200  
Borderline 200-239  
High > 240  
Method:- CHOD-PAP methodology

**InstrumentName:**MISPA PLUS **Interpretation:** Cholesterol measurements are used in the diagnosis and treatments of lipid lipoprotein metabolism disorders.

TRIGLYCERIDES 101.00 mg/dl  
Normal <150  
Borderline high 150-199  
High 200-499  
Very high >500  
Method:- GPO-TOPS methodology

**InstrumentName:**MISPA PLUS **Interpretation :** Triglyceride measurements are used in the diagnosis and treatment of diseases involving lipid metabolism and various endocrine disorders e.g. diabetes mellitus, nephrosis and liver obstruction.

DIRECT HDL CHOLESTEROL 78.90 mg/dl  
Male 35-80  
Female 42-88  
Method:- Selective inhibition Method

**Instrument Name:**MISPA PLUS **Interpretation:** An inverse relationship between HDL-cholesterol (HDL-C) levels in serum and the incidence/prevalence of coronary heart disease (CHD) has been demonstrated in a number of epidemiological studies. Accurate measurement of HDL-C is of vital importance when assessing patient risk from CHD. Direct measurement gives improved accuracy and reproducibility when compared to precipitation methods.

LDL CHOLESTEROL 101.27 mg/dl  
Optimal <100  
Near Optimal/above optimal 100-129  
Borderline High 130-159  
High 160-189  
Very High > 190  
Method:- Calculated Method

VLDL CHOLESTEROL 20.20 mg/dl  
0.00 - 80.00  
Method:- Calculated

T.CHOLESTEROL/HDL CHOLESTEROL RATIO 2.50  
0.00 - 4.90  
Method:- Calculated

LDL / HDL CHOLESTEROL RATIO 1.28  
0.00 - 3.50  
Method:- Calculated

TOTAL LIPID 565.63 mg/dl  
400.00 - 1000.00  
Method:- CALCULATED

1. Measurements in the same patient can show physiological& analytical variations. Three serialsamples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
2. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended
3. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

**Comments:** 1- ATP III suggested the addition of Non HDL Cholesterol (Total Cholesterol – HDL Cholesterol) as an indicator of all VIKARANTJI

**Technologist**  
Page No: 7 of 16

*Tanu*

**DR.TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226





B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME :- **Mrs. SARITA DEVI** 4814881@p3healthdiagnostics1@gmail.com

Patient ID :-12223042 Date :- 11/02/2023 09:02:28

Age :- 31 Yrs 7 Mon 13 Days

Ref. By Doctor:-BANK OF BARODA

Sex :- Female

Lab/Hosp :-

Company :- Mr.MEDIWHEEL

Final Authentication : 11/02/2023 18:29:58

**BIOCHEMISTRY**

**LIVER PROFILE WITH GGT**

SERUM BILIRUBIN (TOTAL) Method:- DMSO/Diazo	0.62	mg/dL	Infants : 0.2-8.0 mg/dL Adult - Up to - 1.2 mg/dL
SERUM BILIRUBIN (DIRECT) Method:- DMSO/Diazo	0.12	mg/dL	Up to 0.40 mg/dL
SERUM BILIRUBIN (INDIRECT) Method:- Calculated	0.50	mg/dl	0.30-0.70
SGOT Method:- IFCC	25.7	U/L	Men- Up to - 37.0 Female - Up to - 31.0
SGPT Method:- IFCC	28.6	U/L	Men- Up to - 40.0 Female- Up to - 31.0
SERUM ALKALINE PHOSPHATASE Method:- DGKC - SCE	72.40	U/L	42.00 - 110.00
SERUM GAMMA GT Method:- Szasz methodology Instrument Name Randox Rx Imola Interpretation: Elevations in GGT levels are seen earlier and more pronounced than those with other liver enzymes in cases of obstructive jaundice and metastatic neoplasms. It may reach 5 to 30 times normal levels in intra-or post-hepatic biliary obstruction. Only moderate elevations in the enzyme level (2 to 5 times normal) are observed with infectious hepatitis.	18.90	U/L	5.00 - 32.00
SERUM TOTAL PROTEIN Method:- Direct Biuret Reagent	6.45	g/dl	5.10 - 8.00
SERUM ALBUMIN Method:- Bromocresol Green	5.01	g/dl	3.50 - 5.50
SERUM GLOBULIN Method:- CALCULATION	1.44 L	gm/dl	2.20 - 3.50
A/G RATIO	3.48 H		1.30 - 2.50

**Interpretation :** Measurements obtained by this method are used in the diagnosis and treatment of a variety of diseases involving the liver, kidney and bone marrow as well as other metabolic or nutritional disorders.

**Note :-** These are group of tests that can be used to detect the presence of liver disease, distinguish among different types of liver disorders, gauge the extent of known liver damage, and monitor the response to treatment. Most liver diseases cause only mild symptoms initially, but these diseases must be detected early. Some tests are associated with functionality (e.g., albumin), some with cellular integrity (e.g., transaminase), and some with conditions linked to the biliary tract (gamma-glutamyl transferase and alkaline phosphatase). Conditions with elevated levels of ALT and AST include hepatitis A,B ,C ,paracetamol toxicity etc. Several biochemical tests are useful in the evaluation and management of patients with hepatic dysfunction. Some or all of these measurements are also carried out (usually about twice a year for routine cases) on those individuals taking certain medications, such as anticonvulsants, to ensure that the medications are not adversely impacting the person's liver.

VIKARANTJI

**Technologist**  
Page No: 9 of 16

*Tanu Rungta*  
**DR. TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226

Print Copy



B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME :- Mrs. SABITA DEVI	Patient ID :- 12223042	Date :- 11/02/2023	09:02:28
Age :- 31 Yrs 7 Mon 13 Days	Ref. By Doctor :- BANK OF BARODA		
Sex :- Female	Lab/Hosp :-		
	Company :- Mr.MEDIWHEEL		

Final Authentication : 11/02/2023 18:29:58

**BIOCHEMISTRY**

**RFT / KFT WITH ELECTROLYTES**

SERUM UREA 18.60 mg/dl 10.00 - 50.00  
Method:- Urease/GLDH

**InstrumentName:** HORIBA CA 60 **Interpretation :** Urea measurements are used in the diagnosis and treatment of certain renal and metabolic diseases.

SERUM CREATININE 0.97 mg/dl Males : 0.6-1.50 mg/dl  
Females : 0.6 -1.40 mg/dl  
Method:- Jaffe's Method

**Interpretation :**  
Creatinine is measured primarily to assess kidney function and has certain advantages over the measurement of urea. The plasma level of creatinine is relatively independent of protein ingestion, water intake, rate of urine production and exercise. Depressed levels of plasma creatinine are rare and not clinically significant.

SERUM URIC ACID 3.35 mg/dl 2.40 - 7.00

**InstrumentName:** HORIBA YUMIZEN CA60 Daytona plus **Interpretation:** Elevated Urate: High purine diet, Alcohol, Renal insufficiency, Drugs, Polycythaemia vera, Malignancies, Hypothyroidism, Rare enzyme defects, Downs syndrome, Metabolic syndrome, Pregnancy, Gout.

SODIUM 137.0 mmol/L 135.0 - 150.0  
Method:- ISE

**Interpretation:** Decreased sodium - Hyponatraemia Causes include: fluid or electrolyte loss, Drugs, Oedematous states, Legionnaire's disease and other chest infections, pseudonatremia, Hyperlipidaemias and paraproteinaemias, endocrine diseases, SIADH.

POTASSIUM 4.66 mmol/L 3.50 - 5.50  
Method:- ISE

**Interpretation:** A. Elevated potassium (hyperkalaemia)• Artefactual, Physiological, Drugs, Pathological states, Renal failure Adrenocortical insufficiency, metabolic acidoses, very high platelet or white cell counts B. Decreased potassium (hypokalaemia) Drugs, Liquoric, Diarrhoea and vomiting, Metabolic alkalosis, Corticosteroid excess, Oedematous state, Anorexia nervosa/bulimia

CHLORIDE 106.7 mmol/L 94.0 - 110.0  
Method:- ISE

**Interpretation:** Used for Electrolyte monitoring.

SERUM CALCIUM 9.55 mg/dl 8.10 - 11.50  
Method:- Colorimetric method

**InstrumentName:** Rx Daytona plus **Interpretation:** Serum calcium levels are believed to be controlled by parathyroid hormone and vitamin D. Increases in serum PTH or vitamin D are usually associated with hypercalcemia. Hypocalcemia may be observed in hypoparathyroidism, nephrosis and pancreatitis.

SERUM TOTAL PROTEIN 7.01 g/dl 5.10 - 8.00  
Method:- Biuret Reagent

**Technologist**

Page No: 10 of 16

*Tanu Rungta*  
**DR.TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226

Print Copy





B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



+ NAME :- **MS. SARITA DEVI** 481488@maxcare1diagnostics1@gmail.com

Patient ID :-12223042 Date :- 11/02/2023 09:02:28

Age :- 31 Yrs 7 Mon 13 Days

Ref. By Doctor:-BANK OF BARODA

Sex :- Female

Lab/Hosp :-

Company :- Mr.MEDIWHEEL

Final Authentication : 11/02/2023 18:29:58

**BIOCHEMISTRY**


SERUM ALBUMIN Method:- Bromocresol Green	5.01	g/dl	3.50 - 5.50
SERUM GLOBULIN Method:- CALCULATION	1.44	L gm/dl	2.20 - 3.50
A/G RATIO	3.48	H	1.30 - 2.50

**Interpretation** : Measurements obtained by this method are used in the diagnosis and treatment of a variety of diseases involving the liver, kidney and bone marrow as well as other metabolic or nutritional disorders.

**INTERPRETATION**

Kidney function tests are group of tests that can be used to evaluate how well the kidneys are functioning. Creatinine is a waste product that comes from protein in the diet and also comes from the normal wear and tear of muscles of the body. In blood, it is a marker of GFR .in urine, it can remove the need for 24-hourcollections for many analytes or be used as a quality assurance tool to assess the accuracy of a 24-hour collection Higher levels may be a sign that the kidneys are not working properly. As kidney disease progresses, the level of creatinine and urea in the bloodincreases. Certain drugs are nephrotoxic hence KFT is done before and after initiation of treatment with these drugs.

Low serum creatinine values are rare; they almost always reflect low muscle mass.



VIKARANTJI

**Technologist**  
Page No: 11 of 16

**DR. TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226

Print Copy





B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023



NAME :- Mrs. SARITA DEVI	Patient ID :-12223042	Date :- 11/02/2023	09:02:28
Age :- 31 Yrs 7 Mon 13 Days	Ref. By Doctor:-BANK OF BARODA		
Sex :- Female	Lab/Hosp :-		
	Company :- Mr.MEDIWHEEL		

Final Authentication : 11/02/2023 18:29:58

**TOTAL THYROID PROFILE**

**IMMUNOASSAY**

Test Name	Value	Unit	Biological Ref Interval
<b>THYROID-TRIiodothyronine T3</b> Method:- ECLIA	1.24	ng/mL	0.70 - 2.04

NOTE-TSH levels are subject to circadian variation, reaching peak levels between 2-4 AM and min between 6-10 PM. The variation is the order of 50% hence time of the day has influence on the measures serum TSH concentration. Dose and time of drug intake also influence the test result. Transient increase in TSH levels or abnormal TSH levels can be seen in some non thyroidal conditions, simultaneous measurement of TSH with free T4 is useful in evaluating differential diagnosis

INTERPRETATION-Ultra Sensitive 4th generation assay 1.Primary hyperthyroidism is accompanied by ↑serum T3 & T4 values along with \* TSH level. 2.Low TSH, high FT4 and TSH receptor antibody (TRAb) +ve seen in patients with Graves disease 3.Low TSH, high FT4 and TSH receptor antibody (TRAb) -ve seen in patients with Toxic adenoma/Toxic Multinodular goiter 4.High TSH, Low FT4 and Thyroid microsomal antibody increased seen in patients with Hashimotos thyroiditis 5.High TSH, Low FT4 and Thyroid microsomal antibody normal seen in patients with Iodine deficiency/Congenital T4 synthesis deficiency 6.Low TSH, Low FT4 and TRH stimulation test -Delayed response seen in patients with Tertiary hypothyroidism 7.Primary hypothyroidism is accompanied by ↓ serum T3 and T4 values & \*serum TSH levels 8.Normal T4 levels accompanied by \* T3 levels and low TSH are seen in patients with T3 Thyrotoxicosis 9.Normal or \* T3 & \* T4 10.Normal T3 & T4 along with \* TSH indicate mild / Subclinical Hyperthyroidism . 11.Normal T3 & \* T4 along with \* TSH is seen in Hypothyroidism . 12.Normal T3 & T4 levels with \* TSH indicate Mild / Subclinical Hypo

DURING PREGNANCY - REFERENCE RANGE for TSH in uIU/mL (As per American Thyroid Association) 1st Trimester : 0.10-2.50 uIU/mL 2nd Trimester : 0.20-3.00 uIU/mL 3rd Trimester : 0.30-3.00 uIU/mL The production, circulation, and disintegration of thyroid hormones are altered throughout the stages of pregnancy.

REMARK-Assay results should be interpreted in context to the clinical condition and associated results of other investigations. Previous treatment with corticosteroid therapy may result in lower TSH levels while thyroid hormone levels are normal. Results are invalidated if the client has undergone a radionuclide scan within 7-14 days before the test. Abnormal thyroid test findings often found in critically ill patients should be repeated after the critical nature of the condition is resolved. TSH is an important marker for the diagnosis of thyroid dysfunction. Recent studies have shown that the TSH distribution progressively shifts to a higher concentration with age, and it is debatable whether this is due to a real change with age or an increasing proportion of unrecognized thyroid disease in the elderly. \*\*\*

<b>THYROID THYRONINE (T4)</b> Method:- ECLIA	8.30	uIU/mL	5.10 - 14.10
---	------	--------	--------------

NOTE-TSH levels are subject to circadian variation, reaching peak levels between 2-4 AM and min between 6-10 PM. The variation is the order of 50% hence time of the day has influence on the measures serum TSH concentration. Dose and time of drug intake also influence the test result. Transient increase in TSH levels or abnormal TSH levels can be seen in some non thyroidal conditions, simultaneous measurement of TSH with free T4 is useful in evaluating differential diagnosis

INTERPRETATION-Ultra Sensitive 4th generation assay 1.Primary hyperthyroidism is accompanied by ↑serum T3 & T4 values along with \* TSH level. 2.Low TSH, high FT4 and TSH receptor antibody (TRAb) +ve seen in patients with Graves disease 3.Low TSH, high FT4 and TSH receptor antibody (TRAb) -ve seen in patients with Toxic adenoma/Toxic Multinodular goiter 4.High TSH, Low FT4 and Thyroid microsomal antibody increased seen in patients with Hashimotos thyroiditis 5.High TSH, Low FT4 and Thyroid microsomal antibody normal seen in patients with Iodine deficiency/Congenital T4 synthesis deficiency 6.Low TSH, Low FT4 and TRH stimulation test -Delayed response seen in patients with Tertiary hypothyroidism 7.Primary hypothyroidism is accompanied by ↓ serum T3 and T4 values & \*serum TSH levels 8.Normal T4 levels accompanied by \* T3 levels and low TSH are seen in patients with T3 Thyrotoxicosis 9.Normal or \* T3 & \* T4 10.Normal T3 & T4 along with \* TSH indicate mild / Subclinical Hyperthyroidism . 11.Normal T3 & \* T4 along with \* TSH is seen in Hypothyroidism . 12.Normal T3 & T4 levels with \* TSH indicate Mild / Subclinical Hypo

DURING PREGNANCY - REFERENCE RANGE for TSH in uIU/mL (As per American Thyroid Association) 1st Trimester : 0.10-2.50 uIU/mL 2nd Trimester : 0.20-3.00 uIU/mL 3rd Trimester : 0.30-3.00 uIU/mL The production, circulation, and disintegration of thyroid hormones are altered throughout the stages of pregnancy.

REMARK-Assay results should be interpreted in context to the clinical condition and associated results of other investigations. Previous treatment with corticosteroid therapy may result in lower TSH levels while thyroid hormone levels are normal. Results are invalidated if the client has undergone a radionuclide scan within 7-14 days before the test. Abnormal thyroid test findings often found in critically ill patients should be repeated after the critical nature of the condition is resolved. TSH is an important marker for the diagnosis of thyroid dysfunction. Recent studies have shown that the TSH distribution progressively shifts to a higher concentration with age, and it is debatable whether this is due to a real change with age or an increasing proportion of unrecognized thyroid disease in the elderly.

<b>TSH</b> Method:- ECLIA	1.281	uIU/mL	0.350 - 5.500
------------------------------	-------	--------	---------------

NOTE-TSH levels are subject to circadian variation, reaching peak levels between 2-4 AM and min between 6-10 PM. The variation is the order of 50% hence time of the day has influence on the measures serum TSH concentration. Dose and time of drug intake also influence the test result. Transient increase in TSH levels or abnormal TSH levels can be seen in some non thyroidal conditions, simultaneous measurement of TSH with free T4 is useful in evaluating differential diagnosis

INTERPRETATION-Ultra Sensitive 4th generation assay  
1.Primary hyperthyroidism is accompanied by ↑serum T3 & T4 values along with ↑ TSH level.

*Tanu Rungta*

**DR.TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226

**Technologist**  
Page No: 15 of 16

Print Copy





B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023




NAME :- <b>Ms. SABITA DEVI</b>	diagnostics1@gmail.com	Patient ID :-12223042	Date :- 11/02/2023	09:02:28
Age :- 31 Yrs 7 Mon 13 Days		Ref. By Doctor:-BANK OF BARODA		
Sex :- Female		Lab/Hosp :-		
		Company :- Mr.MEDIWHEEL		

Final Authentication : 11/02/2023 18:29:58

**CLINICAL PATHOLOGY**

Test Name	Value	Unit	Biological Ref Interval
<b>Urine Routine</b>			
<b><u>PHYSICAL EXAMINATION</u></b>			
COLOUR	PALE YELLOW		PALE YELLOW
APPEARANCE	Clear		Clear
<b><u>CHEMICAL EXAMINATION</u></b>			
REACTION(PH)	5.0		5.0 - 7.5
SPECIFIC GRAVITY	1.015		1.010 - 1.030
PROTEIN	NIL		NIL
SUGAR	NIL		NIL
BILIRUBIN	NEGATIVE		NEGATIVE
UROBILINOGEN	NORMAL		NORMAL
KETONES	NEGATIVE		NEGATIVE
NITRITE	NEGATIVE		NEGATIVE
<b><u>MICROSCOPY EXAMINATION</u></b>			
RBC/HPF	NIL	/HPF	NIL
WBC/HPF	2-3	/HPF	2-3
EPITHELIAL CELLS	2-3	/HPF	2-3
CRYSTALS/HPF	ABSENT		ABSENT
CAST/HPF	ABSENT		ABSENT
AMORPHOUS SEDIMENT	ABSENT		ABSENT
BACTERIAL FLORA	ABSENT		ABSENT
YEAST CELL	ABSENT		ABSENT
OTHER	ABSENT		ABSENT



VIKARANTJI

**Technologist**  
Page No: 12 of 16

**DR. TANU RUNGTA**  
MD (Pathology)  
RMC No. 17226

Print Copy



<b>NAME:</b>	<b>MRS. SARITA DEVI</b>	<b>AGE/SEX</b>	<b>31 YRS/F</b>
<b>REF.BY</b>	<b>BANK OF BARODA</b>	<b>DATE</b>	<b>11/02/2023</b>

**CHEST X RAY (PA VIEW)**

Bilateral lung fields appear clear.

Bilateral costo-phrenic angles appear clear.

Cardiothoracic ratio is normal.


Thoracic soft tissue and skeletal system appear unremarkable.

Soft tissue shadows appear normal.

**IMPRESSION:** No significant abnormality is detected.

**DR.SHALINI GOEL**  
**M.B.B.S, D.N.B (Radiodiagnosis)**  
**RMC No.: 21954**













B-14, Vidhyadhar Enclave - II, Near Axis Bank  
Central Spine, Vidhyadhar Nagar, Jaipur - 302023  
+91 141 4824885 maxcarediagnostics1@gmail.com

<b>MRS. SARITA DEVI</b>	<b>Age: 31 Y/F</b>
<b>Registration Date: 11/02/2023</b>	<b>Ref. by: BANK OF BARODA</b>

**ULTRASOUND OF WHOLE ABDOMEN**

**Liver** is of normal size (14.1 cm). **Echo-texture is increased.** No focal space occupying lesion is seen within liver parenchyma. Intra hepatic biliary channels are not dilated. Portal vein diameter is normal.

**Gall bladder** is well distended. Wall is not thickened. No calculus or mass lesion is seen in gall bladder. Common bile duct is not dilated.

**Pancreas** is of normal size and contour. Echo-pattern is normal. No focal lesion is seen within pancreas.

**Spleen** is of normal size and shape (10.9 cm). Echotexture is normal. No focal lesion is seen.

**Kidneys** are normally sited and are of normal size and shape. Cortico-medullary echoes are normal. No focal lesion is seen. Collecting system does not show any dilatation or calculus.

**Right kidney** is measuring approx. 11.1 x 4.1 cm.

**Left kidney** is measuring approx. 11.7 x 4.3 cm.

**Urinary bladder** does not show any calculus or mass lesion.

**Uterus** is retroverted and normal in size (measuring approx. 8.0 x 4.7 x 5.7 cm).

Myometrium shows normal echo -pattern. No focal space occupying lesion is seen. Endometrial echo is normal. Endometrial thickness is 10.7 mm.

**Bilateral ovaries are bulky with peripherally arranged, non-dominant (<6 mm) follicles and mildly echogenic stroma – possibility of PCOD.**

**Left ovary** measures 4.0 x 2.9 x 2.8 cm, **volume 17.6 cc.**

**Right ovary** measures 2.8 x 2.7 x 2.2 cm, **volume 12.4 cc**

No enlarged nodes are visualized. No retro-peritoneal lesion is identified.

No significant free fluid is seen in pouch of Douglas.



**IMPRESSION:**

- **Polycystic ovarian morphology as described above – possibility of PCOD. Adv: Clinical/hormonal assay correlation.**
- **Grade 1 fatty liver.**

**DR.SHALINI GOEL**

**M.B.B.S, D.N.B (Radiodiagnosis)**





FINDINGS: Normal Sinus Rhythm

Vent Rate : 67 bpm; PR Interval : 134 ms; QRS Duration: 136 ms; QT/QTc Int : 353/375 ms

P-QRS-T axis: 61 • 55 • 28 • (Deg)

Comments :

*Handwritten signature*

TUNL

Dr. Naresh Kumar T. Chhankha

RMC No.: 35703

MBBS, DIP. CARDIO (ESCORTS)

D.E.M. (RCGP-UK)



Protocol : BRUCE

History :

Stage	Stage Time (Min:Sec)	Phase Time (Min:Sec)	Speed (mph)	Grade (%)	METs	H.R. (bpm)	B.P. (mmHg)	R.P.P. x100	PVC	Comments
Supine					1.0	74	120/80	88	-	
HV					1.0	86	120/80	103	-	
Standing					1.0	82	120/80	98	-	
HV					1.0	80	120/80	96	-	
EXStart					1.0	82	120/80	98	-	
Stage 1	3:01	3:02	1.7	10.0	4.7	106	130/80	137	-	
Stage 2	3:01	6:02	2.5	12.0	7.1	126	140/80	176	-	
PeakEX	1:41	7:42	3.4	14.0	8.8	161	150/85	241	-	
Recovery	1:00		0.0	0.0	1.2	103	150/85	154	-	
Recovery	2:00		0.0	0.0	1.0	81	160/90	129	-	
Recovery	3:00		0.0	0.0	1.0	80	150/85	120	-	
Recovery	4:00		0.0	0.0	1.0	83	140/85	116	-	

Findings :

Exercise Time : 07:41

Max HR Attained : 161 bpm 85% of Max Predictable HR 189


Max BP : 160/90(mmHg)

Max Workload attained : 8.8(Fair Effort Tolerance)

TMT is negative for RMI.

Advice/Comments:

*afat 2023*



Dr. Naresh Kumar Mohanka

RMC No.: 35703

MBBS, DIP. CARDIO (ESCORTS)

D.E.M. (RCGP-UK)





B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur

1322407/MRS SARITA DEVI

31 Yrs/Female

0 Kg/0 Cms

Date: 11-Feb-2023 01:03:50 PM

4X 80 ms Post J

HR: 74 bpm

METS: 1.0

BP: 120/80

MPHR: 39% of 189

Speed: 0.0 mph

Grade: 0.0%

Raw ECG

BRUCE

(1.0-35)Hz

Ex Time 00:39



BLC : On

Notch : On

Supine

10.0 mm/mV

25 mm/Sec.





B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur

1322407/MRS SARITA DEVI

31 Yrs/Female

0 Kg/0 Cms

Date: 11-Feb-2023 01:03:50 PM

4X 80 ms Post J

HR: 83 bpm  
METS: 1.0  
BP: 120/80

MPHR: 43% of 189  
Speed: 0.0 mph  
Grade: 0.0%


Raw ECG  
BRUCE  
(1.0-35)Hz

Ex Time 01:16  
BLC :On  
Notch :On

Standing  
10.0 mm/mV  
25 mm/Sec.



V5  
0.4





HEALTH SOLUTIONS LLP  
B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur

1322407/MRS SARTIYA DEVI  
31 Yrs/Female  
0 Kg/0 Cms  
Date: 11-Feb-2023 01:03:50 PM  
4X 80 ms Post J

HR: 88 bpm  
METS: 1.0  
BP: 120/80

MPHR: 46% of 189  
Speed: 0.0 mph  
Grade: 0.0%


Raw ECG  
BRUCE  
(1.0-35)Hz

Ex Time 01:09  
BLC : On  
Notch : On

HV  
10.0 mm/mV  
25 mm/Sec.



V5  
0.4





'S HEALTH SOLUTIONS LLP  
B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur

1322407/MRS SARITA DEVI

31 Yrs/Female

0 Kg/0 Cms

Date: 11-Feb-2023 01:03:50 PM

4X 80 ms Post J

HR: 106 bpm

METS: 4.7

BP: 130/80

MPHR: 56% of 189

Speed: 1.7 mph

Grade: 10.0%

Raw ECG

BRUCE

(1.0-35)Hz

Ex Time 02:59


BLC : On

Notch : On

BRUCE: Stage 1(3:00)

10.0 mm/mV

25 mm/Sec.



V5  
0.4



HEALTH SOLUTIONS LLP  
B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur

1322407/MRS SARITA DEVI  
31 Yrs/Female  
0 Kg/0 Cms  
Date: 11-Feb-2023 01:03:50 PM  
4X 80 ms Post J

HR: 125 bpm  
METS: 7.1  
BP: 140/80

MPHR: 66% of 189  
Speed: 2.5 mph  
Grade: 12.0%





Raw ECG  
BRUCE  
(1.0-35)Hz

Ex Time 05:59  
BLC : On  
Notch : On

BRUCE: Stage 2(3:00)  
10.0 mm/mV  
25 mm/Sec.



V5  
0.4





'S HEALTH SOLUTIONS LLP  
B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur

1322407/MRS SARITA DEVI

31 Yrs/Female

0 Kg/0 Cms

Date: 11-Feb-2023 01:03:50 PM

4X 80 ms Post J


HR: 161 bpm  
METS: 8.8  
BP: 150/85

MPHR: 85% of 189  
Speed: 3.4 mph  
Grade: 14.0%

Raw ECG  
BRUCE  
(1.0-35)Hz

Ex Time 07:39  
BLC : On  
Notch : On

BRUCE: PeakEx(1:39)  
10.0 mm/mV  
25 mm/Sec.



V5  
0.1



HR: 104 bpm

METS: 1.3

BP: 150/85

MPHR: 55% of 189

Speed: 0.0 mph

Grade: 0.0%

Raw ECG

BRUCE

(1.0-35)Hz

Ex Time 07:41

BLC: On

Notch: On





Recovery(1:00)

10.0 mm/mv

25 mm/Sec.



V5  
0.2





HEALTH SOLUTIONS LLP  
B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur

1322407/MRS SARITA DEVI  
31 Yrs/Female  
0 Kg/0 Cms  
Date: 11-Feb-2023 01:03:50 PM  
4X 80 ms Post J

HR: 81 bpm  
METs: 1.0  
BP: 160/90

MPHR: 42% of 189  
Speed: 0.0 mph  
Grade: 0.0%




Raw ECG  
BRUCE  
(1.0-35)Hz

Ex Time 07:41  
BLC : On  
Notch : On

Recovery(2:00)  
10.0 mm/mV  
25 mm/Sec.



V5  
-0.3





'S HEALTH SOLUTIONS LLP  
B-14, Vidhyadhar Nagar Enclave, Phase -2, Jaipur  
1322407/MRS SARITA DEVI  
31 Yrs/Female  
0 Kg/0 Cms  
Date: 11-Feb-2023 01:03:50 PM  
4X 80 ms Post J

HR: 79 bpm  
METs: 1.0  
BP: 150/85

MPHR: 41% of 189  
Speed: 0.0 mph  
Grade: 0.0%





Raw ECG  
BRUCE  
(1.0-35)Hz

Ex Time 07:41  
BLC : On  
Notch : On

Recovery(3:00)  
10.0 mm/mV  
25 mm/Sec.



V5  
-0.4





1322407/MRS SARTI A DEVI  
 31 Yrs/Female  
 0.Kg/0 Cms  
 Date: 11-Feb-2023 01:03:50 PM  
 4X 80 ms Post J

HR: 83 bpm  
 METS: 1.0  
 BP: 140/85

MPHR: 43% of 189  
 Speed: 0.0 mph  
 Grade: 0.0%


Raw ECG  
 BRUCE  
 (1.0-35)Hz

Ex Time 07:41  
 BLC : On  
 Notch : On

Recovery(4:00)  
 10.0 mm/mV  
 25 mm/Sec.







V5  
 -0.3









I II III aVR aVL aVF V1 V2 V3 V4 V5 V6













R

12223042 MRS.SARITA DEVI 31YRS BANK OF BARODA F  
11.FEB.2023  
MAXCARE DIAGNOSTIC (ASSOCIATES OF P3 HEALTH SOLUTIONS LLP)

